AVNP2 protects against cognitive impairments induced by C6 glioma by suppressing tumour associated inflammation in rats
- Submitting institution
-
University of Hertfordshire
- Unit of assessment
- 12 - Engineering
- Output identifier
- 22626721
- Type
- D - Journal article
- DOI
-
10.1016/j.bbi.2020.02.009
- Title of journal
- Brain Behavior and Immunity
- Article number
- -
- First page
- 645
- Volume
- 87
- Issue
- -
- ISSN
- 0889-1591
- Open access status
- Compliant
- Month of publication
- February
- Year of publication
- 2020
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- 5 - Biological Sciences
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
7
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- Antiviral nanoparticles (AVNP) that were engineered using patented Plasma process and produced by the AVNP Consortium (UK-DTI, 2005-10) had undergone animal tests for the first time, funded by the National Natural Science Foundation of China (81771979). AVNP consisted of graphitic carbons conjugated with intermetallic Silver-Copper-Tungsten that was designed with antiviral purpose (SARS-CoV) have proven to also reduce tumour sizes and suppress tumour-associated inflammations in rat models. This research has the potential to bring forward step change for Biomedical and therapeutic industries, introducing Nanoparticles administration in mammalian tissues.
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -